Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

GeneDx Holdings Corp. - Class A Common Stock (NQ: WGS )

77.74 -3.95 (-4.84%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GeneDx Holdings Corp. - Class A Common Stock

< Previous 1 2 3 4 5 Next >
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GeneDx Holdings Corp.
Via GlobeNewswire
Insiders Buying Plus Therapeutics And 2 Other Stocks Under $2
The Dow Jones closed lower by around 40 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
GeneDx Hldgs's Earnings: A Preview
Via Benzinga
Where GeneDx Hldgs Stands With Analysts
Via Benzinga
Why JetBlue Airways Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 80% to $6.14 after the company announced it received notice of acceptance from the Australian patent office for its patent application for... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
GeneDx Reports Third Quarter 2023 Financial Results and Business Highlights
From GeneDx Holdings Corp.
Via GlobeNewswire
Earnings Scheduled For October 30, 2023
Companies Reporting Before The Bell • HSBC Holdings (NYSE:HSBC) is likely to report earnings for its third quarter. 
Via Benzinga
GeneDx to Report Third Quarter 2023 Financial Results on Monday, October 30, 2023
From GeneDx Holdings Corp.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Thursday
  During Thursday's session, 406 companies made new 52-week lows. 
Via Benzinga
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GeneDx Holdings Corp.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Tuesday
  During Tuesday's session, 275 companies made new 52-week lows. 
Via Benzinga
GeneDx Announces Evolution of Executive Leadership Team
Melanie Duquette joining team as Chief Growth Officer to drive commercial excellence, Jennifer Brendel to take new role as Chief of Corporate Affairs amplifying the GeneDx brand and leadership... 
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Announces Industry-Leading Accomplishment of 500,000 Clinical Exomes Sequenced
From GeneDx Holdings Corp.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Wednesday
  Wednesday's session saw 150 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 210 companies reached new 52-week lows. 
Via Benzinga
GeneDx Announces Data Demonstrating that Whole Exome and Genome Sequencing Report Fewer Variants of Uncertain Significance (VUS) than Multi-Gene Panel Testing Published in Genetics in Medicine
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GeneDx Holdings Corp.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  During the Friday's sesion, 157 stocks hit new 52-week lows. 
Via Benzinga
GeneDx Reports Second Quarter 2023 Financial Results and Business Highlights
From GeneDx Holdings Corp.
Via GlobeNewswire
PacBio and GeneDx Launch Research Collaboration with the University of Washington to Study Long-Read Whole Genome Sequencing for Increased Diagnostic Yield in Neonatal Care
Study is first of its kind to compare diagnostic rates across short- and long-read sequencing platforms 
From GeneDx Holdings Corp.; PacBio
Via GlobeNewswire
GeneDx and Prognos Health Announce Strategic Partnership to Help Rare Disease Patients More Rapidly Gain Access to Potential Treatment Options
Partnership allows commercial biopharma companies to leverage real-time data within comprehensive Prognos Marketplace to provide available treatment options for patients 
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx to Present New Data on Urine Mitochondrial DNA Testing at the 2023 United Mitochondrial Disease Foundation’s Mitochondrial Medicine Symposium
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Announces New Tool to Help Harness Human Pangenome Diversity for Clinical Interpretation of Variants
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Commends the States of Arizona and Florida for Adding Rapid Whole Genome Sequencing (rWGS) as a Covered Benefit for Medicaid Pediatric Patients
Eight state Medicaid programs now cover rWGS in the pediatric inpatient setting, with active bills in other states 
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx to Participate in Upcoming Investor Conferences in June
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx to Participate in World Orphan Drug Congress Keynote and Panel Presentations
Keynote session to highlight value of GeneDx genomic data and clinical insights to accelerate genetic neurodevelopmental disorder pipeline for Mahzi Therapeutics 
From GeneDx Holdings Corp.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.